An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT06828354 Phase 3 RECRUITING

This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

Details

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 3
Status	RECRUITING
Enrolment	300
Start date	2025-03-13
Completion	2027-12

Conditions

• Ovarian Cancer

Interventions

• SHR-A1811
• Paclitaxel Injection
• Doxorubicin Hydrochloride Liposome Injection
• Gemcitabine Hydrochloride for Injection
• Topotecan Hydrochloride for Injection

Primary outcomes

• Progression free survival (PFS) — From day 1 to 10 months.

Countries

China